Diroximel Fumarate Clinical Trials (2026): 11 Studies for Multiple Sclerosis & Relapsing Forms of MS
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
11 Diroximel Fumarate clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 6 indications (including Multiple Sclerosis & Relapsing Forms of MS) and 13,477 total planned enrollment. 2 Phase 3 Diroximel Fumarate trials are listed. 4 Diroximel Fumarate clinical trials are actively recruiting at 2 U.S. sites across 2 states. Most recent activity: NCT07483632 (Jun 2035).
Where to Participate: All Diroximel Fumarate Trial Sites in the U.S. (2 sites across 2 states)
Every actively recruiting Diroximel Fumaratetrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| CO | University of Colorado Anschutz Medical Campus | Aurora80045 | NCT05658497 | Map |
| NC | IQVIA US Office | Durham27703 | NCT05658497 | Map |
Diroximel Fumarate clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | enrolling by invitation | completed | terminated | not yet recruiting | Total |
|---|---|---|---|---|---|---|---|
| P1 | 2 | 2 | |||||
| P3 | 1 | 1 | 2 | ||||
| N/A | 2 | 2 | 1 | 2 | 7 |
Recruiting Diroximel Fumarate clinical trials (4)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07483632 | VOYAGEA Study to Learn About the Safety of Diroximel Fumarate (DRF) and Dimethyl Fumarate (DMF) and Their Effects on Relapses in Pediatric Participants With Relapsing Forms of Multiple Sclerosis (RMS) | P3 | Relapsing Forms of Multiple Sclerosis | 185 | Nov 2026 |
| NCT05658497 | Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate) | — | Multiple Sclerosis | 908 | Oct 2023 |
| NCT06957808 | FORTUNEInvestigating the Effect of Diroximel Fumarate on Glutathione in Schizophrenia | N/A | Schizophrenia Disorders | 30 | Jan 2025 |
| NCT04676204 | STATURERelationship Between Oral DMT Burden and Adherence in MS | — | Multiple Sclerosis | 323 | Sep 2020 |
Diroximel Fumarate clinical trials by indication
Multiple Sclerosis (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05767736 | MS | N/A | active not recruiting | A Study to Evaluate Long-Term Safety of Vumerity and Tecfidera in Participants With Multiple Sclerosis (MS) |
| NCT05658497 | — | N/A | recruiting | Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate) |
| NCT05688436 | — | N/A | active not recruiting | A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies |
| NCT04676204 | STATURE | N/A | enrolling by invitation | Relationship Between Oral DMT Burden and Adherence in MS |
Relapsing Forms of Multiple Sclerosis (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07483632 | VOYAGE | P3 | not yet recruiting | A Study to Learn About the Safety of Diroximel Fumarate (DRF) and Dimethyl Fumarate (DMF) and Their Effects on Relapses in Pediatric Participants With Relapsing Forms of Multiple Sclerosis (RMS) |
| NCT05083923 | DRF | P3 | completed | A Study of Diroximel Fumarate (DRF) in Adult Participants From the Asia-Pacific Region With Relapsing Forms of Multiple Sclerosis (RMS) |
Relapsing Forms of MS (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04948606 | EXPER-CA/IL | N/A | terminated | Exploring Diroximel Fumarate Real-world Experience in Canada and Israel |
| NCT04746976 | — | N/A | terminated | Study of Diroximel Fumarate in the Real-World Setting |
Schizophrenia Disorders (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06957808 | FORTUNE | N/A | recruiting | Investigating the Effect of Diroximel Fumarate on Glutathione in Schizophrenia |
Healthy Volunteers (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05127564 | DRF | P1 | completed | A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Diroximel Fumarate (DRF) in Chinese and Caucasian Adult Healthy Participants |
Relapsing Remitting Multiple Sclerosis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05181215 | — | P1 | completed | Bioequivalence Study of Bafiertam 190 mg and Vumerity® 462 mg Delayed-Release Capsules in Fasting Healthy Subjects |
Diroximel Fumarate pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| VOYAGE | NCT07483632 | P3 | not yet recruiting | Relapsing Forms of Multiple Sclerosis | 185 | — |
| DRF | NCT05083923 | P3 | completed | Relapsing Forms of Multiple Sclerosis | 136 | — |
Terminated and withdrawn Diroximel Fumarate trials (2)
Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.
- NCT04948606terminatedExploring Diroximel Fumarate Real-world Experience in Canada and Israel
- NCT04746976terminatedStudy of Diroximel Fumarate in the Real-World Setting
All Diroximel Fumarate trials (11)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07483632 | VOYAGE | A Study to Learn About the Safety of Diroximel Fumarate (DRF) and Dimethyl Fumarate (DMF) and Their Effects on Relapses in Pediatric Participants With Relapsing Forms of Multiple Sclerosis (RMS) | P3 | not yet recruiting | 185 | Biogen | Nov 2026 |
| NCT05767736 | MS | A Study to Evaluate Long-Term Safety of Vumerity and Tecfidera in Participants With Multiple Sclerosis (MS) | — | active not recruiting | 10,500 | Biogen | Jun 2024 |
| NCT05658497 | Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate) | — | recruiting | 908 | Biogen | Oct 2023 | |
| NCT05688436 | A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies | — | active not recruiting | 1,178 | Biogen | Sep 2021 | |
| NCT06957808 | FORTUNE | Investigating the Effect of Diroximel Fumarate on Glutathione in Schizophrenia | N/A | recruiting | 30 | King's College London | Jan 2025 |
| NCT04676204 | STATURE | Relationship Between Oral DMT Burden and Adherence in MS | — | enrolling by invitation | 323 | Monash University | Sep 2020 |
| NCT05083923 | DRF | A Study of Diroximel Fumarate (DRF) in Adult Participants From the Asia-Pacific Region With Relapsing Forms of Multiple Sclerosis (RMS) | P3 | completed | 136 | Biogen | Nov 2021 |
| NCT04948606 | EXPER-CA/IL | Exploring Diroximel Fumarate Real-world Experience in Canada and Israel | — | terminated | 64 | Biogen | Dec 2021 |
| NCT04746976 | Study of Diroximel Fumarate in the Real-World Setting | — | terminated | 75 | Biogen | Mar 2021 | |
| NCT05127564 | DRF | A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Diroximel Fumarate (DRF) in Chinese and Caucasian Adult Healthy Participants | P1 | completed | 32 | Biogen | Dec 2021 |
| NCT05181215 | Bioequivalence Study of Bafiertam 190 mg and Vumerity® 462 mg Delayed-Release Capsules in Fasting Healthy Subjects | P1 | completed | 46 | Banner Life Sciences LLC | May 2021 |
Diroximel Fumarate clinical trials: frequently asked questions
- How many Diroximel Fumarate clinical trials are there?
- 11 Diroximel Fumarate clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 3 are actively recruiting participants. 3 are marked completed.
- Are Diroximel Fumarate clinical trials recruiting in 2026?
- Yes — 3 Diroximel Fumarate trials are actively recruiting in 2026, with 2 U.S. sites across 2 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is Diroximel Fumarate being studied for?
- Diroximel Fumarate is being studied for Multiple Sclerosis, Relapsing Forms of MS, Relapsing Forms of Multiple Sclerosis, Adherence, Medication, Schizophrenia Disorders and 2 more. The trials are grouped by indication on this page.
- What phase is Diroximel Fumarate in?
- Diroximel Fumarate clinical trials span 2 Phase 3, 2 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Diroximel Fumarate clinical trials?
- The lead sponsor across the most Diroximel Fumarate trials is Biogen, with 3 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Diroximel Fumarateas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: